Abstract

Bovine respiratory disease (BRD) is the most important illness of feedlot cattle. Disease management targets the associated bacterial pathogens, Mannheimia haemolytica, Mycoplasma bovis, Pasteurella multocida, Histophilus somni, and Trueperella pyogenes. We conducted a cross-sectional study to measure the frequencies of antimicrobial-resistant BRD pathogens using a collaborative network of veterinarians, industry, government, and a diagnostic laboratory. Seven private veterinary practices in southern Alberta collected samples from both living and dead BRD-affected animals at commercial feedlots. Susceptibility testing of 745 isolates showed that 100% of the M. haemolytica, M. bovis, P. multocida, and T. pyogenes isolates and 66.7% of the H. somni isolates were resistant to at least one antimicrobial class. Resistance to macrolide antimicrobials (90.2% of all isolates) was notable for their importance to beef production and human medicine. Multidrug resistance (MDR) was high in all target pathogens with 47.2% of the isolates resistant to four or five antimicrobial classes and 24.0% resistance to six to nine classes. We compared the MDR profiles of isolates from two feedlots serviced by different veterinary practices. Differences in the average number of resistant classes were found for M. haemolytica (p < 0.001) and P. multocida (p = 0.002). Compared to previous studies, this study suggests an increasing trend of resistance in BRD pathogens against the antimicrobials used to manage the disease in Alberta. For the veterinary clinician, the results emphasize the importance of ongoing susceptibility testing of BRD pathogens to inform treatment protocols. Surveillance studies that collect additional epidemiological information and manage sampling bias will be necessary to develop strategies to limit the spread of resistance.

Highlights

  • Bovine respiratory disease (BRD) in newly received calves continues to be the most predominant health issue for North American beef production, with incidences that range from 5 to 44% and estimated costs to producers at $13.90 per animal [1]

  • GEN, gentamycin/NEO, neomycin/SPE, spectinomycin; DAN, danofloxacin/ENRO, enrofloxacin; TYLT, tylosin/TUL, tulathromycin/TIL, tilmicosin; PEN, penicillin/AMP, ampicillin/XNL, ceftiofur; CLI, clindamycin; FFN, florfenicol; SXT, trimethoprim sulpha/SDM, sulphadimethoxine; OXY, oxytetracycline; CTET, chlortetracycline; TIA, tiamulin. aCategorization of Antimicrobial Drugs Based on Importance in Human Medicine—Veterinary Drug Directorate. bPathogen minimum inhibitory concentration breakpoints from CLSI standards. cNo CLSI breakpoint for this bovine respiratory disease pathogen/antimicrobial combination, notes susceptibility

  • This study was a successful collaboration of private practice veterinarians, industry, government, and a diagnostic laboratory for monitoring AMR in BRD pathogens from feedlot cattle in southern Alberta and quantified the phenotypic AMR in BRDaffected feedlot cattle

Read more

Summary

Introduction

Bovine respiratory disease (BRD) in newly received calves continues to be the most predominant health issue for North American beef production, with incidences that range from 5 to 44% and estimated costs to producers at $13.90 per animal [1]. The empirical use of broad-spectrum antimicrobials is currently considered essential for the prevention and treatment of BRD [4]. Resistance to multiple antimicrobial classes has been associated with large, mobile genetic elements in M. haemolytica and P. multocida [8,9,10]. Poor response to antimicrobial therapy threatens livestock health and welfare, may lead to increased antimicrobial use (AMU), increases production costs, and potentially contributes to the dissemination of antimicrobial-resistant genes to other bacteria in cattle and possibly the environment [11, 12]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call